Assessment of Ivy Leaf Extracts for Antibacterial Activity against Pathogenic Bacteria: No Evidence of Efficacy
DOI:
https://doi.org/10.54361/ljmr.20.1.11Keywords:
Ivy Leaf Extracts, Antibacterial Activity, Pathogenic BacteriaAbstract
Background: The global spread of antibiotic resistance in bacteria such as Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa has created an urgent need for new antimicrobial treatments. This is especially critical in Libya, where infections from multidrug-resistant pathogens are common. Aim: This study aimed to investigate the in vitro antibacterial potential of aqueous and alcoholic extracts from ivy leaves (Hedera helix) against these key pathogenic bacteria. Materials and Methods: We prepared extracts using dried ivy leaves and tested them against clinical bacterial isolates using standard disc diffusion and broth macro-dilution methods to determine the minimum inhibitory concentration (MIC). Results: Our results showed a complete absence of antibacterial activity. No zones of inhibition were observed in the disc diffusion assay, and the MIC for all extracts against all bacterial strains was determined to be greater than 100%, the highest concentration tested. Conclusion: These findings indicate that the therapeutic value of H. helix leaf extracts, while well- established for respiratory symptoms, does not include a direct antibacterial effect against the pathogens tested. The search for novel antimicrobials from botanical sources should focus on other plants and more advanced extraction techniques.
Downloads
References
1. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens. 2021 Oct 12;10(10):1310. doi: 10.3390/pathogens10101310. PMID: 34684258; PMCID: PMC8541462.
2. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MAA. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare (Basel). 2023 Jul 5;11(13):1946. doi: 10.3390/healthcare11131946. PMID: 37444780; PMCID: PMC10340576.
3. Agena MB, Ibrahim KM, Alsonosi AM, Saad MT, Elgamoudi BA. Investigating the role of cytoskeletal dynamics in Cronobacter invasion: a study of Caco-2 and H4 cell lines. Appl Microbiol. 2025;5:89. doi: 10.3390/applmicrobiol5030089.
4. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013 Dec;13(12):1057-98. doi: 10.1016/S1473-3099(13)70318-9.
5. Zorgani A, Elahmer O, Franka E, Grera A, Abudher A, Ghenghesh KS. Detection of meticillin-resistant Staphylococcus aureus among healthcare workers in Libyan hospitals. Journal of Hospital Infection [Internet]. 2009 Jul 29;73(1):91–92. Available from: https://doi.org/10.1016/j.jhin.2009.06.019
6. Ahmed MO, Elramalli AK, Baptiste KE, Daw MA, Zorgani A, Brouwer E, Willems RJL, Top J. Whole Genome Sequence Analysis of the First Vancomycin-Resistant Enterococcus faecium Isolates from a Libyan Hospital in Tripoli. Microb Drug Resist. 2020 Nov;26(11):1390-1398. doi: 10.1089/mdr.2019.0095. Epub 2020 Mar 16. PMID: 32181678.
7. Kieffer N, Ahmed MO, Elramalli AK, Daw MA, Poirel L, Álvarez R, Nordmann P. Colistin-resistant carbapenemase-producing isolates among Klebsiella spp. and Acinetobacter baumannii in Tripoli, Libya. J Glob Antimicrob Resist. 2018 Jun;13:37-39. doi: 10.1016/j.jgar.2018.02.020. Epub 2018 Mar 9. PMID: 29530497
8. Okimoto N, Hayashi T, Ishiga M, Nanba F, Kishimoto M, Yagi S, Kurihara T, Asaoka N, Tamada S. Clinical features of Proteus mirabilis pneumonia. J Infect Chemother. 2010 Oct;16(5):364-6. doi: 10.1007/s10156-010-0059-3. Epub 2010 May 26. PMID: 20502932.
9. Ullah S, Saadaat R, Hamidi H, Haidary AM. Proteus mirabilis: A rare cause of pneumonia, radiologically mimicking malignancy of the lung. Clin Case Rep. 2023 Sep 19;11(9):e7937. doi: 10.1002/ccr3.7937. PMID: 37736480; PMCID: PMC10509339.
10. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev. 1999 Oct;12(4):564-82. doi: 10.1128/CMR.12.4.564. PMID: 10515903; PMCID: PMC88925.
11. Gibbons S. Anti-staphylococcal plant natural products. Nat Prod Rep. 2004 Apr;21(2):263-77. doi: 10.1039/b212695h. Epub 2004 Mar 1. PMID: 15042149.
12. Abouzeed YM, Elfahem AA, Zgheel FS, Ahmed MO. Antibacterial in-vitro activities of selected medicinal plants against methicillin resistant Staphylococcus aureus from Libyan environment. J Environ Anal Toxicol. 2013;3:7. doi:10.4172/2161-0525.1000194
13. El-Mokasabi zeed YM, Elfahem AA, Zgheel FS, Ahmed MO. Antibacterial in-vitro activities of selected medicinal plants against methicillin resistant Staphylococcus aureus from Libyan environment. J Environ Anal Toxicol. 2013;3:7. doi:10.4172/2161-0525.1000194
14. European Medicines Agency (EMA). Assessment report on Hedera helix L., Folium. 2018
15. Schaefer A, Kehr MS, Giannetti BM, Bulitta M, Staiger C. A randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract (EA 575®) vs. placebo in the treatment of adults with acute cough. Pharmazie. 2016 Sep 1;71(9):504-509. doi: 10.1691/ph.2016.6712. PMID: 29441845
16. Lang C, Röttger-Lüer P, Staiger C. A Valuable Option for the Treatment of Respiratory Diseases: Review on the Clinical Evidence of the Ivy Leaves Dry Extract EA 575®. Planta Med. 2015 Aug;81(12-13):968-74. doi: 10.1055/s-0035-1545879. Epub 2015 Apr 15. PMID: 25875509.
17. Schmidt M, Thomsen M, Schmidt U. Suitability of ivy extract for the treatment of paediatric cough. Phytother Res. 2012 Dec;26(12):1942-7. doi: 10.1002/ptr.4671. Epub 2012 Apr 25. PMID: 22532491.
18. Holzinger F, Chenot JF. Systematic review of clinical trials assessing the effectiveness of ivy leaf (hedera helix) for acute upper respiratory tract infections. Evid Based Complement Alternat Med. 2011;2011:382789. doi: 10.1155/2011/382789. Epub 2010 Oct 3. PMID: 20976077; PMCID: PMC2957147.
19. Baharara H, Moghadam AT, Sahebkar A, Emami SA, Tayebi T, Mohammadpour AH. The Effects of Ivy (Hedera helix) on Respiratory Problems and Cough in Humans: A Review. Adv Exp Med Biol. 2021;1328:361-376. doi: 10.1007/978-3-030-73234-9_23. PMID: 34981489.
20. Lim KJA, Cabajar AA, Lobarbio CFY, Taboada EB, Lacks DJ. Extraction of bioactive compounds from mango (Mangifera indica L. var. Carabao) seed kernel with ethanol-water binary solvent systems. J Food Sci Technol. 2019 May;56(5):2536-2544. doi: 10.1007/s13197-019-03732-7. Epub 2019 Apr 1. PMID: 31168135; PMCID: PMC6525705.
21. Fadhila SI, Hayati EK, Rafi M, Sabarudin A. Effect of ethanol–water concentration as extraction solvent on antioxidant activity of Acalypha indica. Al Kimiya J Ilmu Kim Dan Terapan. 2023;10(2):133-142. doi:10.15575/ak.v10i2.30081.
22. Kemmerich B, Eberhardt R, Stammer H. Efficacy and tolerability of a fluid extract combination of thyme herb and ivy leaves and matched placebo in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled clinical trial. Arzneimittelforschung. 2006;56(9):652-60. doi: 10.1055/s-0031-1296767. PMID: 17063641.
23. Schönknecht K, Fal AM, Mastalerz-Migas A, Joachimiak M, Doniec Z. efficacy of dry extract of ivy leaves in the treatment of productive cough. Wiad Lek. 2017;70(6 pt 1):1026-1033. PMID: 29478973.
24. Stauss-Grabo M, Atiye S, Warnke A, Wedemeyer RS, Donath F, Blume HH. Observational study on the tolerability and safety of film-coated tablets containing ivy extract (Prospan® Cough Tablets) in the treatment of colds accompanied by coughing. Phytomedicine. 2011 Apr 15;18(6):433-6. doi: 10.1016/j.phymed.2010.11.009. Epub 2011 Jan 5. PMID: 21211950.
25. Breijyeh Z, Jubeh B, Karaman R. Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules. 2020 Mar 16;25(6):1340. doi: 10.3390/molecules25061340. PMID: 32187986; PMCID: PMC7144564.
26. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308. doi: 10.1586/eri.13.12. PMID: 23458769.
27. Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 2005 Nov;26(5):343-56. doi: 10.1016/j.ijantimicag.2005.09.002.
28. Shariati A, Arshadi M, Khosrojerdi MA, Abedinzadeh M, Ganjalishahi M, Maleki A, Heidary M, Khoshnood S. The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. PMID: 36620240; PMCID: PMC9815622.
29. Al-Ouqaili MTS, Hussein RA, Kanaan BA, Al-Neda ATS. Investigation of carbapenemase-encoding genes in Burkholderia cepacia and Aeromonas sobria isolates from nosocomial infections in Iraqi patients. PLoS One. 2025 Aug 29;20(8):e0315490. doi: 10.1371/journal.pone.0315490. PMID: 40880429; PMCID: PMC12396648.
30. AL-Daher RI. Prevalence of carbapenemase genes in Klebsiella pneumoniae isolated from urine samples in Iraq. Int J Med Sci Dent Health. 2025;11(10):165-171. doi:10.55640/ijmsdh-11-10-19
31. Stock I. Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains. J Chemother. 2003 Feb;15(1):12-26. doi: 10.1179/joc.2003.15.1.12. PMID: 12678409.
32. Salama LA, Saleh HH, Abdel-Rhman SH, Barwa R, Hassan R. Assessment of typing methods, virulence genes profile and antimicrobial susceptibility for clinical isolates of Proteus mirabilis. Ann Clin Microbiol Antimicrob. 2025 Jan 15;24(1):4. doi: 10.1186/s12941-024-00770-8. PMID: 39815271; PMCID: PMC11734338.
33. Hammoudi AA, Hussein AN. Antibiotic resistance of Klebsiella pneumoniae isolates from inpatients with burn infections. J Wasit Sci Med. 2023;11(1):133-145. doi:10.31185/jwsm.448.
34. Gajic I, Kabic J, Kekic D, Jovicevic M, Milenkovic M, Mitic Culafic D, Trudic A, Ranin L, Opavski N. Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods. Antibiotics (Basel). 2022 Mar 23;11(4):427. doi: 10.3390/antibiotics11040427. PMID: 35453179; PMCID: PMC9024665
35. Howard A, Hughes DM, Green PL, Velluva A, Gerada A, Maskell S, Buchan IE, Hope W. Personalised antimicrobial susceptibility testing with clinical prediction modelling informs appropriate antibiotic use. Nat Commun. 2024 Nov 21;15(1):9924. doi: 10.1038/s41467-024-54192-3. PMID: 39572574; PMCID: PMC11582675.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Abdulgader Dhawi, Mahmoud Bashir Agena, Abdulali Taweel, Bushra E Aboukhadeer, Omaima B. Hassan , Dias A. Aljaffal , Wasan A. Shaqman (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
